Predictive value of systemic immune-inflammation index and serum lactoferrin for postoperative survival in older patients with colon cancer

Table 1 General patient characteristics

Project	Value or n (%)	χ²/t	P value
Age (years)	72.46 ± 6.02	-	-
Sex (male/female)	36 (58.06)/26 (41.94)	1.161	0.281
BMI (kg/m²)	22.53 ± 2.28	-	-
Smoking history (yes/no)	27 (43.55)/35 (56.45)	0.968	0.325
Drinking history (yes/no)	23 (37.10)/39 (62.90)	1.419	0.234
Hypertension (yes/no)	25 (40.32)/37 (59.68)	2.258	0.133
Diabetes (yes/no)	15 (24.19)/47 (75.81)	1.613	0.204
Coronary heart disease (yes/no)	8 (12.90)/54 (87.10)	0.645	0.422
COPD (yes/no)	5 (8.06)/57 (91.94)	0.218	0.641
Tumor size (cm)	4.73 ± 1.21	-	-
TNM staging (II/III)	26/36	0.95	0.331
Degree of differentiation (high/medium/Low)	13/34/15	2.323	0.313
Neural/vascular invasion (yes/no)	19 (30.65)/43 (69.35)	1.774	0.183
NEU (× 109/L)	4.12 ± 1.08	-	-
LYM (× 109/L)	1.64 ± 0.42	-	-
PLT (× 109/L)	212.36 ± 54.27	-	-
SII	869.42 ± 211.57	-	-
LF (μg/mL)	3.89 ± 0.86	-	-
ECOG performance status (0-1/≥ 2)	48 (77.4%)/14 (22.6%)	Calculated	Calculated
Charlson comorbidity index	3.2 ± 1.1	-	-
Adjuvant chemotherapy	51 (82.3%)	-	-
FOLFOX regimen	33 (65% of chemo)	-	-
CAPOX regimen	18 (35% of chemo)	-	-
MSI-H status	9 (14.5%)	Calculated	Calculated

P < 0.05 indicated significant difference. SII: Systemic immune-inflammation index; TNM: Traditional tumor, node, metastasis; BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; NEU: Neutrophil; LYM: Lymphocyte; PLT: Platelet; LF: Lactoferrin; ECOG: Eastern Cooperative Oncology Group performance status.